Letters

Throughout the year, the AHA comments on a vast number of proposed and interim final rules put forth by the federal regulatory agencies. In addition, AHA communicates with federal legislators to convey the hospital field's position on potential legislative changes that would impact patients and patient care. Below are the most recent letters from the AHA to these bodies.

Latest

The American Hospital Association submits comments on how the Federal Communications Commission can encourage health care provider participation in its Connected Care Pilot Program.
AHA's comment on the Office of Inspector General’s Request for Information on ways to modify or add regulatory safe harbors and exceptions for the Anti-Kickback Statute and beneficiary inducement Civil Monetary Penalty. 
The AHA is deeply disappointed in certain proposals that CMS has chosen to set forth in this proposed rule for the CY 2019 outpatient prospective payment system (OPPS), which run afoul of the law and rely on the most cursory of analyses and policy rationales. Taken together, they would have a chilling effect on beneficiary access to care and new technologies, while also dramatically increasing regulatory burden.
AHA responds to the Department of Health and Human Services Request for Information regarding the facilitation of a public-private dialogue to increase innovation and investment in the health care sector.
The AHA voiced support for a Federal Communications Commission proposal to create a $100 million pilot program to support telehealth for low-income Americans, calling the Connected Care Pilot Program “a critical next step towards delivering affordable telehealth services to those Americans who need it the most.”
Download the comment letter (PDF)
AHA comments on the Centers for Medicare & Medicaid Services’ calendar year 2019 proposed rule for the Home Health prospective payment system.
AHA comments on the Drug Enforcement Administration’s (DEA) notice of proposed rulemaking on aggregate production quotas for Schedule I and II controlled substances.